Glaucoma nursing: intraocular pressure, eye drop administration, and optic nerve monitoring

Glaucoma is the leading cause of irreversible blindness worldwide, affecting an estimated 80 million people. It encompasses a group of optic neuropathies characterized by progressive loss of retinal ganglion cells and their axons, producing a characteristic pattern of optic disc cupping and visual field defects. In the United States, primary open-angle glaucoma (POAG) — the most common form — affects approximately 3 million people, with African Americans at three to four times higher risk than White Americans. Nurses encounter glaucoma patients across outpatient ophthalmology settings, primary care, and acute care when patients present with acute angle-closure attacks. This reference covers glaucoma classification, pathophysiology, assessment, nursing interventions, pharmacology, surgical management, and NCLEX-focused clinical reasoning points.

Quick reference	Open-angle glaucoma	Acute angle-closure glaucoma
Onset	Insidious; asymptomatic until late	Sudden, acute emergency
Pain	None	Severe eye and periorbital pain
IOP	Mildly to moderately elevated (often 20–30 mmHg)	Markedly elevated (often >40–50 mmHg)
Pupil	Normal	Mid-dilated, fixed, non-reactive
Vision	Peripheral field loss (central preserved until late)	Blurred, halos around lights
Cornea	Clear	Steamy/cloudy (corneal edema)
Treatment	Chronic; eye drops ± surgery	Ophthalmologic emergency; IV acetazolamide, IV mannitol, pilocarpine, laser iridotomy
Prevalence	~90% of glaucoma cases	~10% of glaucoma cases

Pathophysiology

Aqueous humor dynamics

Intraocular pressure (IOP) is maintained by the balance between aqueous humor production and outflow. Aqueous humor is produced by the ciliary body (approximately 2–3 µL/min) and drains primarily through two pathways:

Trabecular meshwork (conventional pathway): aqueous flows from the posterior chamber, through the pupil into the anterior chamber, then through the trabecular meshwork at the iridocorneal angle into Schlemm’s canal, and ultimately into the episcleral venous system. This accounts for approximately 75–90% of outflow.
Uveoscleral (unconventional) pathway: aqueous percolates through the ciliary muscle bundles and absorbs into the uveal vasculature. This pathway is enhanced by prostaglandin analogs.

Normal IOP ranges from 10–21 mmHg. Elevated IOP occurs when aqueous outflow is impaired — either through obstruction of the trabecular meshwork (open-angle glaucoma) or blockage of the iridocorneal angle (angle-closure glaucoma).

Optic nerve damage mechanism

Elevated IOP damages retinal ganglion cell axons at the lamina cribrosa — a mesh-like structure at the optic nerve head through which axons exit the eye. Proposed mechanisms include:

Mechanical compression: elevated pressure directly compresses axons and disrupts axoplasmic transport, leading to ganglion cell death
Vascular ischemia: elevated IOP compresses ocular blood supply, causing ischemic optic neuropathy
Glutamate excitotoxicity: dying ganglion cells release glutamate, which triggers excitotoxic death in adjacent cells

Approximately 40% of retinal ganglion cells must be lost before visual field defects become detectable by standard perimetry — explaining why glaucoma is characteristically asymptomatic until significant damage has occurred.

Normal-tension glaucoma

An important subset of POAG — normal-tension glaucoma (NTG) — occurs when progressive optic nerve damage and typical visual field loss develop despite IOP consistently below 21 mmHg. This accounts for approximately one-third of POAG cases and underscores that IOP is not the only pathogenic factor. Vascular dysregulation and autoimmune mechanisms play additional roles.

Classification

Primary open-angle glaucoma (POAG)

The most common form in the US. The iridocorneal angle is open on gonioscopy, but trabecular meshwork resistance is increased. IOP rises gradually. No pain, no redness. Peripheral vision loss is insidious — patients frequently do not notice until 40–50% of ganglion cells are lost. By the time central vision is affected, end-stage disease is present.

Risk factors for POAG:

Age ≥60 years
African American or Hispanic ethnicity
Family history of glaucoma (first-degree relative)
Elevated IOP (ocular hypertension)
Thin central corneal thickness (<555 µm)
Vertical cup-to-disc ratio >0.5

Acute angle-closure glaucoma (AACG)

The iridocorneal angle closes abruptly, blocking aqueous outflow. IOP rises sharply — often to 40–70 mmHg within hours. This is a genuine ophthalmic emergency. Permanent visual loss can occur within hours of onset if not treated.

Classic precipitants of acute angle-closure:

Pupillary dilation (anticholinergic medications, dim lighting, emotional stress)
Anatomically narrow angles (more common in hyperopic/farsighted patients, Asian populations, and women)
Supine positioning (shifts lens forward)

Presenting symptoms: sudden severe unilateral eye pain, frontal headache, nausea and vomiting, blurred vision with halos around lights, red eye, and a steamy/cloudy cornea. Vomiting and headache can mislead clinicians toward neurologic diagnoses.

Secondary glaucomas

Open- or closed-angle glaucoma caused by identifiable ocular or systemic pathology:

Pseudoexfoliation glaucoma: exfoliative material deposits on lens and trabecular meshwork; most common secondary glaucoma worldwide
Pigmentary glaucoma: pigment granules from iris float posteriorly and clog the trabecular meshwork; common in young myopic men
Neovascular glaucoma: new blood vessels grow over the trabecular meshwork, typically from diabetic retinopathy or central retinal vein occlusion
Inflammatory (uveitic) glaucoma: inflammatory cells and debris obstruct outflow
Steroid-induced glaucoma: topical, periocular, or systemic corticosteroids increase IOP in approximately 40% of users

Nursing assessment

IOP measurement and monitoring

Normal IOP: 10–21 mmHg. The single most important parameter to track in glaucoma management.

Goldmann applanation tonometry: the gold standard, performed by ophthalmologists and optometrists. A flat-tipped probe applanates (flattens) the cornea; the force required correlates with IOP.
Non-contact tonometry (air-puff): used in primary care and screening settings; less accurate but acceptable for screening.
iCare rebound tonometer: commonly used in outpatient ophthalmology nursing practice; probe tip makes brief contact with the cornea; can be performed without anesthetic drops. Nurses may be trained to use this device for IOP spot checks.

Nursing role: document IOP at every visit. Compare to patient’s target pressure (set by the ophthalmologist — typically a 20–30% reduction from baseline or below 18 mmHg for most POAG patients). Report IOP above target to the ophthalmologist.

Visual field assessment

Automated perimetry (Humphrey Visual Field analysis) maps peripheral and central visual field loss. Nurses review printed field reports for:

Pattern deviation: areas of loss worse than age-matched norms
Mean deviation (MD): overall field loss — values below −6 dB indicate significant loss
Reliability indices: fixation losses, false positives, false negatives — an unreliable test cannot be interpreted

Educate patients that visual field testing requires sustained concentration over 5–10 minutes. Field results are the primary measure of disease progression used by ophthalmologists to adjust treatment.

Optic disc assessment

Ophthalmologists assess the optic disc with a slit lamp and dilated fundus exam. Key parameters:

Cup-to-disc ratio (CDR): the vertical ratio of the central cup to the disc diameter. A CDR >0.6, asymmetry between eyes of >0.2, or progressive enlargement of the cup raises concern for glaucomatous damage.
ISNT rule: normally, the inferior rim is thickest, followed by superior, nasal, then temporal. Glaucoma preferentially narrows the inferior and superior rims first.
Disc hemorrhages: small splinter hemorrhages at the disc margin indicate active glaucomatous progression.

Medication review

A thorough medication history is essential because multiple drug classes affect IOP:

Drugs that raise IOP (may worsen glaucoma):

Topical and systemic corticosteroids (including inhaled and nasal steroids)
Anticholinergic agents (benztropine, oxybutynin, diphenhydramine, tricyclic antidepressants) — can precipitate angle-closure by dilating the pupil
Sympathomimetics (pseudoephedrine, phenylephrine) — pupil dilation risk in narrow-angle patients
Topiramate — can cause secondary angle-closure through anterior displacement of the lens-iris diaphragm

Drugs that lower IOP (used therapeutically):

Prostaglandin analogs, beta-blockers, alpha-2 agonists, carbonic anhydrase inhibitors, Rho kinase inhibitors (see Pharmacology section)

Nursing interventions

Eye drop administration — the foundational nursing skill

Correct technique is critical to efficacy and safety:

Wash hands thoroughly before handling any ophthalmic medication
Tilt patient’s head back or have patient lie supine; instruct to look upward
Pull lower eyelid down gently to form a conjunctival pocket (lower fornix)
Instill one drop into the lower conjunctival sac — not directly onto the cornea or onto the sclera (drops roll off)
Nasolacrimal occlusion (punctal occlusion): immediately after instillation, have the patient close their eye and apply gentle pressure with one finger to the inner corner of the eye (the punctum) for 1–2 minutes. This is the most important technique nursing often omits — it prevents systemic absorption of the drug through the nasolacrimal duct into the nasopharyngeal mucosa and is especially critical for beta-blocker eye drops (topical timolol can cause bradycardia, bronchospasm, and heart failure exacerbation if systemically absorbed in susceptible patients)
Wait 5 minutes between different eye drops — multiple medications need time to absorb before the next drop washes away the previous one
Remove contact lenses before instilling drops (especially prostaglandin analogs, which can discolor soft lenses). Wait 15 minutes before reinserting.

Managing acute angle-closure glaucoma (nursing emergency response)

Acute angle-closure is an ophthalmologic emergency. Nursing actions:

Position patient supine — gravity pulls the lens slightly posterior, marginally widening the angle
Notify ophthalmology immediately — do not delay for additional nursing assessment
Prepare and administer ordered medications in rapid sequence:
- IV acetazolamide (carbonic anhydrase inhibitor): reduces aqueous production acutely
- IV mannitol (osmotic agent): draws fluid from the vitreous, reducing IOP
- Topical pilocarpine 1–2%: constricts the pupil (miotic), pulling the iris away from the trabecular meshwork and reopening the angle — apply after IOP begins to fall (pilocarpine is poorly effective when IOP is very high because the ischemic iris sphincter cannot respond)
- Topical beta-blocker (timolol 0.5%)
- Topical alpha-2 agonist (brimonidine)
Assess and document IOP serially with rebound tonometer
Pain management: this attack is extremely painful — ensure analgesia is ordered and administered
Prepare patient for laser peripheral iridotomy (LPI): the definitive acute treatment — a laser creates a small hole in the peripheral iris, providing an alternative aqueous drainage route and permanently relieving pupillary block. Bilateral LPI is typically performed to prevent future attacks in the fellow eye.

Patient teaching: glaucoma eye drop adherence

Non-adherence to glaucoma eye drops is the most common cause of preventable vision loss in glaucoma. Key teaching points:

Drops are lifelong: open-angle glaucoma has no cure — eye drops control IOP but do not stop the underlying disease. Stopping drops allows IOP to rise and damage to resume.
Asymptomatic does not mean controlled: patients frequently feel no symptoms from elevated IOP and discontinue drops when they feel fine. Reinforce that the disease is silently damaging the optic nerve.
Timing matters: some drops are dosed once daily (prostaglandin analogs — evening), others twice daily (most beta-blockers, alpha-2 agonists). Consistency of timing improves IOP control.
Side effect counseling: prostaglandin analogs commonly cause periorbital skin darkening, iris color change (permanent in hazel eyes), and eyelash growth — these are cosmetic effects that patients must be warned about to prevent discontinuation.
Storage: most glaucoma drops are stored at room temperature; some (travoprost, latanoprost) should be refrigerated before opening.

Post-operative nursing care (trabeculectomy / tube shunt)

When medications fail to control IOP, surgical intervention creates a new drainage pathway.

Trabeculectomy creates a small opening (bleb) in the sclera under the conjunctiva that allows aqueous to filter out and absorb. Post-operative nursing care:

IOP monitoring: target IOP in early post-operative period may be set very low (6–12 mmHg) to allow bleb formation
Bleb assessment: a functioning bleb appears as an elevated, avascular bleb under the upper eyelid. A flat, vascular bleb suggests failure. The nurse should not touch or compress the bleb.
Positioning: some surgeons restrict patients from lying on the operative side
Medications: post-operative topical antibiotics and corticosteroids are prescribed; the nurse verifies correct instillation technique
Infection warning: blebitis (bleb infection) and endophthalmitis are the most serious long-term complications. Teach the patient to report immediate redness, pain, or reduced vision to the ophthalmologist.

Pharmacology

Drug class	Examples	Mechanism	Key nursing considerations
Prostaglandin analogs (first-line)	Latanoprost (Xalatan), bimatoprost (Lumigan), travoprost (Travatan Z), tafluprost	Increase uveoscleral outflow by relaxing ciliary muscle; most potent IOP-lowering class (25–35% reduction)	Dose once daily, evening (maximizes IOP-lowering effect); permanent iris color change in hazel eyes (warn patient); periorbital skin darkening; eyelash growth; refrigerate before opening; avoid in uveitis; remove contacts 15 min before reinserting
Beta-blockers	Timolol (Timoptic), betaxolol (Betoptic), carteolol	Decrease aqueous humor production by blocking beta-2 receptors on ciliary body epithelium; 20–25% IOP reduction	CRITICAL: systemic absorption via nasolacrimal duct can cause bradycardia, bronchospasm (contraindicated in asthma, COPD, second/third-degree heart block); teach punctal occlusion after each drop; betaxolol is beta-1 selective (safer in mild respiratory disease); monitor heart rate and respiratory status; generally dosed twice daily
Alpha-2 agonists	Brimonidine (Alphagan P), apraclonidine	Decrease aqueous production and increase uveoscleral outflow; 20–25% IOP reduction	CNS depression — caution in elderly and children (children can develop sedation, hypotension, bradycardia — avoid in children under 2); avoid concurrent MAO inhibitors (hypertensive crisis risk); punctal occlusion important; dosed twice to three times daily
Carbonic anhydrase inhibitors (topical)	Dorzolamide (Trusopt), brinzolamide (Azopt)	Inhibit carbonic anhydrase II in ciliary body → reduce bicarbonate and aqueous production; 15–20% IOP reduction	Sulfonamide derivative — contraindicated in sulfa allergy; metallic taste common; stinging on instillation (brinzolamide suspension better tolerated); dosed twice to three times daily
Carbonic anhydrase inhibitors (oral/IV)	Acetazolamide (Diamox), methazolamide	Same mechanism; systemic; used for acute angle-closure or when topical therapy insufficient	Sulfa allergy contraindication; causes metabolic acidosis, hypokalemia, renal stones; paresthesias (tingling) in hands and feet (sign of metabolic acidosis); avoid in sickle cell disease; monitor electrolytes
Rho kinase inhibitors	Netarsudil (Rhopressa)	Increase conventional trabecular outflow and reduce episcleral venous pressure; 20–25% IOP reduction	Newest drug class (FDA 2017); conjunctival hyperemia (redness) very common — warn patients; corneal verticillata (whorled deposits) may appear — benign; once daily dosing (evening)
Combination drops	Cosopt (dorzolamide + timolol), Combigan (brimonidine + timolol), Simbrinza (brinzolamide + brimonidine)	Additive IOP lowering; improve adherence	Carry monitoring requirements of both component drugs; simplify regimen but nurse must understand interactions of both components
Osmotic agents	Mannitol IV, glycerin PO	Hyperosmotic agents create osmotic gradient drawing fluid from vitreous → lower IOP rapidly; used in acute emergencies	IV mannitol (1–2 g/kg over 30–60 min): monitor urine output, fluid balance, serum sodium; contraindicated in heart failure and anuria; filter is required for IV mannitol; monitor for pulmonary edema in elderly; glycerin PO is alternative when IV access is unavailable (avoid in diabetics — high caloric load)

NCLEX tips

Acute angle-closure = ophthalmic emergency. The classic triad: sudden severe eye pain + nausea and vomiting + mid-dilated fixed pupil. The nurse’s first action is to notify the ophthalmologist immediately and position the patient supine while preparing medications. Do not wait for a full nursing assessment.
Timolol eye drops can cause systemic beta-blockade. Topical ophthalmic timolol is absorbed through the nasolacrimal duct and can cause bradycardia, bronchospasm, and heart failure exacerbation. Teaching punctal occlusion after administration prevents this. Contraindicated in asthma, COPD, and second/third-degree heart block.
Open-angle glaucoma is painless — that is the danger. Patients lose peripheral vision silently and are frequently non-adherent with drops because they feel no symptoms. The nurse’s role is to educate that lack of symptoms does not mean the disease is controlled.
Never mistake glaucoma medications for routine eye drops. Prostaglandin analogs cause permanent iris color changes. Patients with hazel eyes should be warned that their eye color may permanently darken on the treated side.
Carbonic anhydrase inhibitors (CAIs) are sulfonamide derivatives. Oral acetazolamide and topical dorzolamide are contraindicated in patients with sulfa allergies. NCLEX tests this knowledge in multiple drug class contexts.
Cup-to-disc ratio is the key optic nerve monitoring parameter. A CDR above 0.6 or progressive increase between exams indicates glaucomatous damage. Asymmetry of more than 0.2 between eyes is also clinically significant.
Pilocarpine in acute angle-closure is given AFTER initial IOP reduction. Pilocarpine constricts the pupil and reopens the angle, but the ischemic iris sphincter cannot respond when IOP is very high (>40 mmHg). It is added to the medication cascade after IV mannitol and acetazolamide have begun to lower IOP.
Glaucoma drops require waiting 5 minutes between different agents. When a patient uses multiple eye drops, instilling them back-to-back causes the second drop to wash out the first. The nurse must teach 5-minute intervals between each medication.
Steroid-induced glaucoma is under-recognized. Any patient on chronic corticosteroids (topical ophthalmic, systemic, inhaled, or even nasal) should have IOP monitored. Approximately 40% of the general population are “steroid responders” — their IOP rises with steroid use.
Laser peripheral iridotomy (LPI) is the definitive treatment for angle-closure. A laser-created hole in the peripheral iris allows aqueous to bypass the pupil, permanently relieving pupillary block. The fellow (contralateral) eye is typically treated prophylactically because both eyes usually share the anatomic predisposition.

Patient education priorities

Glaucoma is chronic. There is no cure; drops are a lifelong commitment. Missing doses allows IOP to rise and optic nerve damage to accumulate silently.
Protect remaining vision. Damage already done cannot be reversed. The goal of treatment is preserving what remains, not restoring what is lost.
Report all new medications to the ophthalmologist. Any physician who prescribes medications — including steroids, anticholinergics, and antidepressants — should know the patient has glaucoma.
Annual comprehensive eye exams. IOP, optic disc evaluation, and visual field testing should be performed at the frequency recommended by the ophthalmologist, typically every 3–6 months.
Inform family members. First-degree relatives of POAG patients have a four- to nine-fold increased risk and should be screened starting at age 40.
Eye protection. Trauma to the eye can cause secondary glaucoma. Protective eyewear is recommended for contact sports and power tool use.

Diabetic retinopathy nursing reference — another leading cause of preventable blindness; diabetes also worsens glaucoma prognosis
Cataracts nursing reference — often co-occurs with glaucoma; cataract surgery can lower IOP in narrow-angle patients

References

Weinreb RN, Khaw PT. “Primary open-angle glaucoma.” The Lancet. 2004;363(9422):1711–1720. doi:10.1016/S0140-6736(04)16257-0
Quigley HA, Broman AT. “The number of people with glaucoma worldwide in 2010 and 2020.” British Journal of Ophthalmology. 2006;90(3):262–267. doi:10.1136/bjo.2005.081224
Kass MA, Heuer DK, Higginbotham EJ, et al. “The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.” Archives of Ophthalmology. 2002;120(6):701–713. doi:10.1001/archopht.120.6.701
European Glaucoma Society Terminology and Guidelines for Glaucoma. 5th ed. British Journal of Ophthalmology. 2021;105(Suppl 1):1–169. doi:10.1136/bjophthalmol-2021-egsguidelines
American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Pattern: Primary Open-Angle Glaucoma. San Francisco, CA: American Academy of Ophthalmology; 2020.
Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. “Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis.” Ophthalmology. 2014;121(11):2081–2090. doi:10.1016/j.ophtha.2014.05.013
Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M; Early Manifest Glaucoma Trial Group. “Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.” Archives of Ophthalmology. 2002;120(10):1268–1279. doi:10.1001/archopht.120.10.1268
Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. “Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use.” American Journal of Ophthalmology. 2007;144(4):533–540. doi:10.1016/j.ajo.2007.06.012
Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. “Glaucoma.” The Lancet. 2017;390(10108):2183–2193. doi:10.1016/S0140-6736(17)31469-1
Boland MV, Ervin AM, Friedman DS, et al. “Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force.” Annals of Internal Medicine. 2013;158(4):271–279. doi:10.7326/0003-4819-158-4-201302190-00008
Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E; Early Manifest Glaucoma Trial Group. “Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial.” Archives of Ophthalmology. 2003;121(1):48–56. doi:10.1001/archopht.121.1.48
Coleman AL, Miglior S. “Risk factors for glaucoma onset and progression.” Survey of Ophthalmology. 2008;53(Suppl 1):S3–S10. doi:10.1016/j.survophthal.2008.08.006
Weinreb RN, Aung T, Medeiros FA. “The pathophysiology and treatment of glaucoma: a review.” JAMA. 2014;311(18):1901–1911. doi:10.1001/jama.2014.3192
Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL; Tube versus Trabeculectomy Study Group. “Treatment outcomes in the Tube versus Trabeculectomy (TVT) study after five years of follow-up.” American Journal of Ophthalmology. 2012;153(5):789–803. doi:10.1016/j.ajo.2011.10.026
Prum BE Jr, Rosenberg LF, Gedde SJ, et al. “Primary open-angle glaucoma preferred practice pattern guidelines.” Ophthalmology. 2016;123(1):P41–P111. doi:10.1016/j.ophtha.2015.10.053